Literature DB >> 24385435

Transcriptional regulation of IFN-λ genes in hepatitis C virus-infected hepatocytes via IRF-3·IRF-7·NF-κB complex.

Hai-Chon Lee1, Sowmya Narayanan, Sung-Jae Park, Seung-Yong Seong, Young S Hahn.   

Abstract

Hepatitis C virus (HCV) infection in hepatocytes stimulates innate antiviral responses including the production of type III interferons (IFN-λ), including IL-28A, IL-28B, and IL-29. However, the molecular mechanism(s) regulating the expression of IFN-λ genes in HCV-infected hepatocytes remains undefined. In this study, we examined regulatory elements involved in the induction of IFN-λ genes following HCV infection in hepatocytes and further determined the binding of specific transcription factor(s) to promoter regions of IFN-λ genes. Our studies reveal that the regulatory portion for IL-28A, IL-28B, and IL-29 genes is localized to a 1-kb region in their respective promoters. Notably, interferon regulatory factor (IRF)-3 and -7 are the key transcriptional factors for the induction of IL-28A and IL-28B genes, whereas NF-κB is an additional requirement for the induction of the IL-29 gene. Ligation of Toll-like receptors (TLR) 3, 7, 8, and 9, which also activate IRFs and NF-κB, resulted in more robust production of IFN-λ than that observed with HCV infection, verifying the importance of TLR pathways in IFN-λ production. Furthermore, the addition of IFN-λ to HCV-infected hepatocytes decreased viral replication and produced a concurrent reduction in microRNA-122 (miR-122). The decrease in viral replication was enhanced by the co-administration of IFN-λ and miR-122 inhibitor (miRIDIAN), suggesting that such combinatorial therapies may be beneficial for the treatment of chronic HCV infection.

Entities:  

Keywords:  Cytokines induction; Hepatitis c virus; Interferon; Interferon regulatory factor; NF-κB; Transcription factors; Transcription promoter

Mesh:

Substances:

Year:  2014        PMID: 24385435      PMCID: PMC3931086          DOI: 10.1074/jbc.M113.536102

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

Review 2.  Toll-like receptor signalling.

Authors:  Shizuo Akira; Kiyoshi Takeda
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

3.  Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species.

Authors:  Robert S Tacke; Hai-Chon Lee; Celeste Goh; Jeremy Courtney; Stephen J Polyak; Hugo R Rosen; Young S Hahn
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

4.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

Authors:  Sergei V Kotenko; Grant Gallagher; Vitaliy V Baurin; Anita Lewis-Antes; Meiling Shen; Nital K Shah; Jerome A Langer; Faruk Sheikh; Harold Dickensheets; Raymond P Donnelly
Journal:  Nat Immunol       Date:  2002-12-16       Impact factor: 25.606

5.  Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures.

Authors:  Svetlana Marukian; Linda Andrus; Timothy P Sheahan; Christopher T Jones; Edgar D Charles; Alexander Ploss; Charles M Rice; Lynn B Dustin
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

6.  HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.

Authors:  Emmanuel Thomas; Veronica D Gonzalez; Qisheng Li; Ankit A Modi; Weiping Chen; Mazen Noureddin; Yaron Rotman; T Jake Liang
Journal:  Gastroenterology       Date:  2012-01-13       Impact factor: 22.682

7.  Hepatitis C virus NS3/4A protease blocks IL-28 production.

Authors:  Qiang Ding; Bing Huang; Jie Lu; Yong-Jun Liu; Jin Zhong
Journal:  Eur J Immunol       Date:  2012-09       Impact factor: 5.532

8.  Hepatitis C virus promotes T-helper (Th)17 responses through thymic stromal lymphopoietin production by infected hepatocytes.

Authors:  Hai-Chon Lee; Sung-Sang J Sung; Peter D Krueger; Yoon-Ah Jo; Hugo R Rosen; Steven F Ziegler; Young S Hahn
Journal:  Hepatology       Date:  2013-03-14       Impact factor: 17.425

Review 9.  The immunology of fibrosis.

Authors:  Georg Wick; Cecilia Grundtman; Christina Mayerl; Thomas-Florian Wimpissinger; Johann Feichtinger; Bettina Zelger; Roswitha Sgonc; Dolores Wolfram
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

10.  Silencing of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 promoter methylation.

Authors:  Takeshi Yoshikawa; Akemi Takata; Motoyuki Otsuka; Takahiro Kishikawa; Kentaro Kojima; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Sci Rep       Date:  2012-09-06       Impact factor: 4.379

View more
  26 in total

Review 1.  A proteomics perspective on viral DNA sensors in host defense and viral immune evasion mechanisms.

Authors:  Marni S Crow; Aaron Javitt; Ileana M Cristea
Journal:  J Mol Biol       Date:  2015-02-26       Impact factor: 5.469

Review 2.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

Review 3.  Immune and non-immune responses to hepatitis C virus infection.

Authors:  Jiaren Sun; Ricardo Rajsbaum; MinKyung Yi
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

4.  A new transcription factor ATG10S activates IFNL2 transcription by binding at an IRF1 site in HepG2 cells.

Authors:  Miao-Qing Zhang; Qiong Zhao; Jing-Pu Zhang
Journal:  Autophagy       Date:  2020-01-29       Impact factor: 16.016

5.  The RNA binding protein Quaking represses host interferon response by downregulating MAVS.

Authors:  Kuo-Chieh Liao; Vanessa Chuo; W Samuel Fagg; Shelton S Bradrick; Julien Pompon; Mariano A Garcia-Blanco
Journal:  RNA Biol       Date:  2019-12-19       Impact factor: 4.652

Review 6.  The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections.

Authors:  Adrian Egli; Deanna M Santer; Daire O'Shea; D Lorne Tyrrell; Michael Houghton
Journal:  Emerg Microbes Infect       Date:  2014-07-16       Impact factor: 7.163

7.  Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytes.

Authors:  Jacques Friborg; Petra Ross-Macdonald; Jian Cao; Ryan Willard; Baiqing Lin; Betsy Eggers; Fiona McPhee
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

Review 8.  Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV.

Authors:  Stephen M Laidlaw; Lynn B Dustin
Journal:  Front Immunol       Date:  2014-10-31       Impact factor: 7.561

9.  IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.

Authors:  Fatma Aboulnasr; Sidhartha Hazari; Satyam Nayak; Partha K Chandra; Rajesh Panigrahi; Pauline Ferraris; Srinivas Chava; Ramazan Kurt; Kyongsub Song; Asha Dash; Luis A Balart; Robert F Garry; Tong Wu; Srikanta Dash
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

10.  HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Is Not Associated with SNP rs12979860 of the IL-28B Gene.

Authors:  Antonio C R Vallinoto; Bárbara Brasil Santana; Keyla S G Sá; Tuane C S Ferreira; Rita Catarina M Sousa; Vânia N Azevedo; Rosimar N M Feitosa; Luiz Fernando A Machado; Marluísa O G Ishak; Ricardo Ishak
Journal:  Mediators Inflamm       Date:  2015-11-01       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.